1. Add-On Therapy to Insulin in T1DM Management

3. Program Overview

4. Why Adjunct Therapy is Needed in T1DM

5. Adjunct Therapies: Pramlintide

6. Adjunct Therapies: Metformin

7. Adjunct Therapies: Newer Agents

8. T2DM Therapies for T1DM: SGLT Inhibitors

9. SGLT1/2 Inhibitors

10. Clinical Trials With SGLT Inhibitors for T1DM

11. Clinical Trials With SGLT Inhibitors for T1DM (cont)

12. EASE 2&3 Subgroup Analysis - DKA

13. Patient Experience of SGLT Adjunct Therapy

14. Patient Experience of SGLT Adjunct Therapy (Cont)

15. DKA Risk With SGLT Inhibitors

16. Managing the DKA Risk

17. Managing the DKA Risk (cont)

18. Managing the DKA Risk (cont)

19. STICH Protocol

20. Educating ER Staff

21. CV Benefits of SGLT Inhibitors

22. Managing CV Risk in T1DM

23. Other Considerations

24. Conclusion

25. Abbreviations